Herbal extract shows promise for stiff skin and joints in transplant survivors
NCT ID NCT07606703
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding madecassoside tablets (from the Centella asiatica plant) to standard treatment can help people with a severe form of chronic graft-versus-host disease that causes skin hardening and joint stiffness. About 30 participants aged 14 to 65 will take the tablets three times daily for 6 months. Doctors will check if skin and joint symptoms improve, and monitor safety and quality of life.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC GRAFT VERSUS HOST DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
RECRUITINGWuhan, Hubei, 430022, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can meditation tame the Long-Term side effects of a stem cell transplant?
- Could a liquid form of a Graft-Versus-Host disease drug be as effective as the pill?
- Can a safer dose of an old drug shield vulnerable children from deadly fungal infections?
- Scientists map immune battlefield in chronic GVHD tissue
- Could a rheumatoid arthritis drug tame chronic GVHD and cut steroid use?
- Gene analysis may unlock secrets of bone marrow transplant complication